New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate

Area of Science:

• Nuclear medicine
• Radiopharmacology
• Skeletal imaging

Background:

• Accurate detection of focal bone lesions is crucial for diagnosis and management.
• Technetium-99m (Tc-99m) diphosphonates are widely used radiopharmaceuticals for bone scintigraphy.
• Optimizing radiotracer biodistribution and lesion-to-normal-bone uptake ratios is key for enhanced diagnostic sensitivity.

Purpose of the Study:

• To compare the three-hour biodistribution of six Tc-99m diphosphonate complexes.
• To evaluate their efficacy in detecting focal bone lesions in a rabbit model.
• To identify potential superior alternatives or adjuncts to methylene diphosphonate (MDP).

Main Methods:

• Biodistribution studies were conducted in rabbits with induced tibial lesions.
• Tc-99m labeled diphosphonate complexes were administered, and tissue uptake was measured at three hours.
• Strontium-85 (Sr-85) was used as a reference standard for comparison.
• Lesion-to-normal-bone ratios were calculated to assess imaging contrast.

Main Results:

• N,N-dimethylaminomethylene diphosphonate (DMAD) exhibited a higher lesion/normal bone ratio than MDP, attributed to lower normal bone uptake.
• Hydroxymethane diphosphonate (HDP) and 2,3-dicarboxypropane-1,1-diphosphonate (DPD) showed increased normal bone uptake without improved lesion contrast.
• DPD and HDP demonstrated significantly higher uptake in non-target organs like the liver, kidney, muscle, and red marrow compared to MDP.

Conclusions:

• While DMAD demonstrated improved lesion contrast in this rabbit model, MDP remains the benchmark for general skeletal imaging.
• HDP and DPD do not offer advantages over MDP for all-purpose skeletal imaging due to increased non-target organ uptake.
• Specific diphosphonates may hold potential for specialized applications in bone lesion detection.